Cipla shares under pressure after USFDA import alert on key supplier

USFDA has issued an import alert on the Rodopi unit in Greece operated by Pharmathen, which supplies Lanreotide injection to Cipla. Lanreotide is among Cipla’s top three products in the US market and commands a market share of around 22%.

Leave a Reply

Your email address will not be published. Required fields are marked *